Cell And Gene Therapy Packaging Market Size, Share, Report, 2034

(MENAFN- Straits Research) Cell and Gene Therapy Packaging Market Size & Growth Analysis

The global cell and gene therapy packaging market size was valued at USD 4.21 billion in 2025 and is projected to grow from USD 4.78 billion in 2026 to USD 12.15 billion by 2034, registering a CAGR of 12.39% during the forecast period (2026–2034). North America dominated the cell and gene therapy packaging market with a market share of 43.84% in 2025.

Cell & gene therapy packaging comprises specialized packaging systems designed to protect, preserve, and transport advanced therapy medicinal products (ATMPs), including cell therapies, gene therapies, and tissue-engineered products, throughout the supply chain. They are widely used for cryogenic storage, cold chain transportation, clinical trials, and commercial distribution of personalized and regenerative therapies.

The cell and gene therapy packaging market demand is driven by the growing commercialization of cell and gene therapies, expanding clinical trial activity, and the need for secure cold chain logistics. Advances in cryogenic packaging technologies, increasing regulatory requirements for advanced therapy medicinal products, and expanding biopharmaceutical manufacturing infrastructure are also contributing to cell and gene therapy packaging market growth.

Cell and Gene Therapy Packaging Market Key Takeaways

The North America cell and gene therapy packaging market accounted for a dominant share of 43.84% in 2025. The Asia Pacific cell and gene therapy packaging marketis expected to grow at a CAGR of 13.42% during the forecast period. By packaging type, the cryogenic packaging segment accounted for a share of 57.36% in 2025. By therapy type, the gene therapy segment is expected to grow at a CAGR of 13.56% during the forecast period. By material, the plastic segment accounted for a share of 68.74% in 2025. By end use, the contract development and manufacturing organizations (CDMOs) segment is expected to expand at a CAGR of 13.21% during the forecast period. The US cell and gene therapy packaging market size was valued at USD 1.42 billion in 2025 and is projected to reach USD 1.61 billion in 2026. The Japan cell and gene therapy packaging market size was valued at USD 0.24 billion in 2025 and is projected to reach USD 0.27 billion in 2026.

Cell and Gene Therapy Packaging Market Trends

Increasing Preference for Personalized Therapies

The growing use of personalized cell and gene therapies is driving the adoption of chain of identity packaging across the supply chain. Companies are using unique barcodes, RFID tags, and tamper-evident labels to ensure every therapy remains linked to the correct patient during storage and transportation. This improves product traceability, reduces the risk of product mix-ups, and supports regulatory compliance. For example, Thermo Fisher Scientific offers identification and labeling solutions that support the chain of identity and chain of custody for advanced therapies.

Increasing Adoption of Multi-Temperature Packaging Solutions

The wider use of different cell and gene therapies is encouraging manufacturers to develop packaging that supports multiple temperature ranges. Companies are introducing packaging systems that protect therapies stored under refrigerated, frozen, and cryogenic conditions, allowing a single packaging portfolio to serve different treatment types. This improves logistics efficiency and helps maintain product quality during global distribution.

Impact of Supply Chain Disruption on Cell and Gene Therapy Packaging Market

The cell and gene therapy packaging market is highly exposed to supply chain disruptions due to its reliance on specialized cryogenic packaging systems, validated cold chain materials, and temperature-controlled logistics for advanced therapies. Disruptions in the supply of insulated shippers, cryogenic containers, phase change materials, and qualified packaging components have affected production schedules, increased transportation costs, and delayed the global distribution of time-sensitive cell and gene therapies. The market is witnessing a capacity-constrained recovery, as demand for cell and gene therapy packaging remains strong while the availability of specialized packaging materials, qualified logistics capacity, and cryogenic infrastructure continues to limit the pace of market expansion.

Cell and Gene Therapy Packaging Market Investment and Funding Analysis

The cell and gene therapy packaging market forecasts continued investment activity driven by the growing commercialization of cell and gene therapies, increasing demand for temperature-controlled packaging, and the need for reliable cold chain logistics.

Key Investment and Funding Activities in Cell and Gene Therapy Packaging Market , 2025 – 2026

Company	Funding/Investment (USD)	Details
Syntax Bio	USD 14.4 Million	In June 2026, the company closed an expanded Series A financing round (bringing total funding past USD 25 million) to advance its CRISPR-based Cellgorithm platform and a pancreatic beta cell therapy program targeting type 1 diabetes.
Anocca	USD 46 Million	In August 2025, the company raised USD 46 million (approx. SEK 440 million) to advance the clinical development of its VIDAR-1 TCR-T cell therapy program targeting mutant KRAS in pancreatic cancer.

Source: Secondary Research

Cell and Gene Therapy Packaging Market Dynamics Market Drivers

Commercial Therapy Approvals and Expansion of Cryogenic Logistics Networks Drive Market

Commercial therapy approvals are driving demand for specialized cell and gene therapy packaging. In 2026, the US Food and Drug Administration (FDA) stated that its Center for Biologics Evaluation and Research (CBER) has approved close to 50 cell and gene therapies over the last decade, with approvals continuing in 2026. Each commercial therapy requires validated packaging to maintain product quality during storage and transportation. This is supporting the use of cryogenic packaging, insulated shippers, and temperature-controlled containers. For example, the FDA approved KRESLADI in 2026, requiring specialized cold chain distribution.

Cryogenic logistics networks are supporting the safe distribution of temperature-sensitive cell and gene therapies. Reliable logistics providers require packaging that maintains ultra-low temperatures throughout transportation. This creates demand for insulated shippers, cryogenic containers, and validated thermal packaging solutions. Better logistics infrastructure also helps manufacturers deliver therapies across global treatment centers while maintaining product quality.

Market Restraints

Strict Regulatory Validation Requirements and Limited Standardization of Packaging Systems Restrain Market Expansion

Cell and gene therapy packaging must undergo extensive validation to demonstrate product safety, sterility, and temperature performance before commercial use. The validation process requires additional testing, documentation, and regulatory review, which increases development time and operational costs. This slows the introduction of new packaging solutions and delays their adoption across the market.

Cell and gene therapies use different storage conditions, container formats, and handling requirements. Packaging manufacturers must develop customized solutions instead of standardized packaging for all therapies. This increases production complexity and costs, limiting large-scale adoption of packaging solutions .

Market Opportunities

Point of Care Manufacturing & Cell Banking Services Offer Growth Opportunities to Market Players

Point of care manufacturing creates new opportunities for packaging companies supplying compact and easy-to-handle packaging solutions. Hospitals and healthcare providers require packaging that supports short-distance transportation, temporary storage, and safe handling of patient-specific therapies within medical facilities. This opens new business opportunities for manufacturers developing packaging for decentralized treatment models.

Cell banking services create opportunities for manufacturers of cryogenic packaging and storage solutions. Biobanks, research institutes, and therapy developers require validated packaging to preserve and transport cellular materials under controlled conditions. This allows packaging companies to supply specialized containers for long-term storage and sample movement. In the future, the wider use of cell banking is expected to support demand for high-performance cryogenic packaging. For example, BioLife Solutions provides cryogenic storage and biopreservation solutions used by cell banking organizations.

Market Challenges

Reverse Logistics Management and Product-Specific Packaging Requirements Challenge Growth

Reusable packaging used for cell and gene therapies must be collected, inspected, and returned after each shipment. Managing these reverse logistics processes across multiple countries increases operational complexity and transportation costs. This reduces the efficiency of reusable packaging programs and slows their wider adoption.

Each cell and gene therapy can have different storage temperatures, container formats, and handling procedures. Packaging manufacturers must manage multiple product-specific configurations instead of streamlined production. For example, autologous and allogeneic therapies often require different packaging formats, increasing manufacturing complexity and limiting operational efficiency.

Cell and Gene Therapy Packaging Market Segmentation Analysis By Packaging Type

The cryogenic packaging segment accounted for a share of 57.36% in the Cell and Gene Therapy Packaging Market. This is due to its extensive use in storing and transporting cell and gene therapies under ultra-low temperature conditions.

The insulated shippers & thermal packaging segment is expected to grow at a CAGR of around 12.84% during the forecast period due to the growing movement of temperature-sensitive therapies between manufacturing facilities, clinical trial sites, and treatment centers. Reliable temperature control, reduced risk of temperature excursions, and compatibility with global cold chain logistics continue to support demand for these packaging solutions.

By Therapy Type

The cell therapy segment accounted for a share of 64.28% in 2025 due to the larger number of commercially available cell therapies, active clinical trial programs, and widespread use of cryogenic storage and transportation. Autologous and allogeneic cell therapies require specialized packaging to preserve product quality throughout the supply chain.

The gene therapy segment is expected to grow at a CAGR of 13.56% during the forecast period, driven by the growing number of commercial gene therapy launches and continued progress in rare disease treatments. The need for validated cold chain packaging, secure handling, and controlled transportation is supporting the adoption of specialized packaging solutions for gene therapies.

By Material

The plastic segment accounted for a share of 68.74% in 2025 due to its lightweight design, high durability, and compatibility with cryogenic storage and temperature-controlled transportation. Plastic is widely used in insulated containers, therapy bags, vials, and protective packaging because it provides high impact resistance while maintaining product integrity throughout the supply chain.

The metal segment is expected to grow at a CAGR of around 11.96% during the forecast period due to its extensive use in cryogenic storage vessels, dry vapor shippers, and liquid nitrogen containers. Superior thermal performance, structural strength, and long service life make metal packaging suitable for advanced therapies stored at ultra-low temperatures. The growing use of reusable cryogenic shipping systems continues to support segment adoption.

By End Use

The biopharmaceutical companies segment accounted for a share of 48.93% in 2025 due to its central role in manufacturing, packaging, storage, and global distribution of cell and gene therapies. These companies require validated packaging systems that ensure product integrity, regulatory compliance, and reliable cold chain performance throughout commercial operations.

The contract development and manufacturing organizations (CDMOs) segment is expected to grow at a CAGR of 13.21% during the forecast period, driven by the outsourcing of cell and gene therapy manufacturing and packaging activities. CDMOs require specialized packaging solutions for clinical and commercial shipments, while integrated manufacturing and supply chain services continue to support segment growth.

Cell and Gene Therapy Packaging Regional Outlook North America Cell and Gene Therapy Packaging Market Analysis

North America: Market Dominance Led by Strong Commercialization of Advanced Therapies and Well-Established Cold Chain Infrastructure

The North America cell and gene therapy packaging market accounted for the largest regional share of 43.84% in 2025, driven by the strong commercialization of cell & gene therapies, a well-established cold chain logistics network, and the presence of leading biopharmaceutical manufacturers. The region also benefits from advanced cryogenic storage infrastructure, specialized treatment centers, and stringent product handling standards.

US Cell and Gene Therapy Packaging Market Analysis

The US cell and gene therapy packaging market was valued at USD 1.42 billion in 2025, driven by the commercialization of advanced therapies and the presence of a large number of biopharmaceutical manufacturers and contract development and manufacturing organizations. According to the US Food and Drug Administration (FDA), the Center for Biologics Evaluation and Research (CBER) has approved close to 50 cell and gene therapies over the last decade, with approvals continuing in 2026, supporting demand for specialized packaging solutions.

Canada Cell and Gene Therapy Packaging Market Analysis

The Canada cell and gene therapy packaging market was valued at USD 0.21 billion in 2025, supported by the country's expanding biomanufacturing capabilities and growing investment in advanced therapy research. Canadian healthcare and research institutions require specialized packaging solutions to maintain product integrity during storage and transportation. Continued investment in cold chain infrastructure is supporting market development.

Asia Pacific Cell and Gene Therapy Packaging Market Analysis

Asia Pacific: Fastest Growth Driven by Expanding Biopharmaceutical Manufacturing and Rising Cell Therapy Research

The Asia Pacific cell and gene therapy packaging market is expected to grow at a CAGR of 13.42% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding biopharmaceutical manufacturing, rising investment in cell and gene therapy research, and improving cold chain infrastructure across major economies. Governments and private companies are strengthening local manufacturing capabilities and advanced therapy supply chains.

China Cell and Gene Therapy Packaging Market Analysis

The China cell and gene therapy packaging market was valued at USD 0.33 billion in 2025, supported by strong investment in biopharmaceutical manufacturing, expanding advanced therapy clinical research, and government initiatives promoting biotechnology innovation. The country is strengthening cold chain logistics and specialized manufacturing facilities to support commercial cell and gene therapy production, creating demand for advanced packaging solutions.

India Cell and Gene Therapy Packaging Market Analysis

The India cell and gene therapy packaging market was valued at USD 0.18 billion in 2025, fueled by the development of biotechnology research centers, expansion of GMP-compliant manufacturing facilities, and increasing participation in global cell and gene therapy clinical trials. Growing investment in pharmaceutical cold chain infrastructure is supporting demand for specialized packaging across research and commercial applications.

Japan Cell and Gene Therapy Packaging Market Analysis

The Japan cell and gene therapy packaging market was valued at USD 0.24 billion in 2025, supported by the country's leadership in regenerative medicine, established regulatory pathways for advanced therapies, and advanced healthcare infrastructure. According to Japan's Ministry of Health, Labour and Welfare, Japan continues to support regenerative medicine through an accelerated regulatory framework and a growing number of approved regenerative medicine products.

Competitive Landscape

The cell and gene therapy packaging market competitive landscape is moderately consolidated, with competition concentrated among established cold chain packaging providers, cryogenic logistics companies, and specialized life sciences packaging manufacturers. Leading players compete through advancements in cryogenic packaging technologies, thermal performance, validated shipping systems, and integrated cold chain solutions. Emerging players also focus on reusable packaging platforms, digital shipment monitoring, and customized packaging solutions for advanced therapies. The cell and gene therapy packaging market ecosystem is shaped by stringent regulatory requirements, commercialization of cell and gene therapies, and evolving cold chain logistics.

List of Key and Emerging Players in Cell and Gene Therapy Packaging Market

Cryoport, Inc. (US) CSafe (US) Sofrigam Group (France) Tower Cold Chain (UK) va-Q-tec AG (Germany) Pelican BioThermal LLC (US) Sonoco ThermoSafe (US) Cold Chain Technologies (US) Envirotainer AB (Sweden) World Courier (US) BioLife Solutions, Inc. (US) American Aerogel Corporation (US) DHL Group (Germany) Marken (US) SkyCell AG (Switzerland)

Key Industry Developments

July 2026: Repligen Corporation announced a merger agreement to acquire BioLife Solutions. The transaction expands Repligen's portfolio of biopreservation media, cell processing tools, and cold chain solutions. May 2026: ThermoSafe announced the expansion of its US vacuum insulated panel (VIP) manufacturing capacity to strengthen the production of temperature-controlled packaging for pharmaceuticals, biologics, and cell and gene therapies. February 2026: ThermoSafe launched Orion Express, a reusable temperature-controlled shipping solution designed for time-critical pharmaceutical shipments, including cell and gene therapy applications.

Report Scope

Market Metric	Details & Data (2025-2034)
Market Size in 2025	USD 4.21 Billion
Market Size in 2026	USD 4.78 Billion
Market Size in 2034	USD 12.15 Billion
CAGR	12.39% (2026-2034)
Base Year for Estimation	2025
Historical Data	2022-2024
Forecast Period	2026-2034
Study Period	2022-2034
Dominant Region	North America
Fastest Growing Region	Asia Pacific
Key Market Players	Cryoport, Inc. (US), CSafe (US), Sofrigam Group (France), Tower Cold Chain (UK), va-Q-tec AG (Germany)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Packaging Type, By Therapy Type, By Material, By End Use
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM
Countries Covered	US, Canada, UK, Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

MENAFN24082026004597010906ID1111581162